Sydney Lupkin
From this contributor
Pharma spending on lobbying skyrocketed in Trump’s first quarter
Eight pharmaceutical companies more than doubled their lobbying spending in the first three months of 2017.
Pharma spending on lobbying skyrocketed in Trump’s first quarter
Health companies gave generously to President Trump’s inauguration
Facing acute risks to their businesses from Washington policymakers, health companies spent more than $2 million to buy access to the incoming Trump administration via candlelight dinners, black-tie balls and other inauguration events.
Health companies gave generously to President Trump’s inauguration
Trump’s choice to run food and drug agency has pharma connections
Scott Gottlieb, nominated to lead the U.S. Food and Drug Administration has deep ties to industry, and has worn many other hats in his career.
Trump’s choice to run food and drug agency has pharma connections
Senators call for investigation into possible abuses of Orphan Drug Act
Building on weeks of mounting pressure to address high prescription drug prices, three influential U.S. senators have asked the government’s accountability arm to probe the orphan drug program for potential misuse.
Senators call for investigation into possible abuses of Orphan Drug Act
Former head of FDA concerned about faster drug approvals
Robert Califf, the just-departed commissioner of the U.S. Food and Drug Administration, offers his take on the Trump administration's plans to speed up drug approvals and dramatically reduce regulations at the agency.
Former head of FDA concerned about faster drug approvals
Explore more from The Transmitter
Neurophysiology data-sharing system faces funding cliff
After the primary grant supporting Neurodata Without Borders ends in March 2026, the platform may no longer be maintained or kept up to date.
Neurophysiology data-sharing system faces funding cliff
After the primary grant supporting Neurodata Without Borders ends in March 2026, the platform may no longer be maintained or kept up to date.
A change at the top of SfN as neuroscientists gather in San Diego
Kevin B. Marvel, longtime head of the American Astronomical Society, will lead the Society for Neuroscience after a year of uncertainty in the neuroscience field.
A change at the top of SfN as neuroscientists gather in San Diego
Kevin B. Marvel, longtime head of the American Astronomical Society, will lead the Society for Neuroscience after a year of uncertainty in the neuroscience field.
How will neuroscience training need to change in the future?
Training in computational neuroscience, data science and statistics will need to expand, say many of the scientists we surveyed. But that must be balanced with a more traditional grounding in the scientific method and critical thinking. Researchers noted that funding concerns will also affect training, especially for people from underrepresented groups.
How will neuroscience training need to change in the future?
Training in computational neuroscience, data science and statistics will need to expand, say many of the scientists we surveyed. But that must be balanced with a more traditional grounding in the scientific method and critical thinking. Researchers noted that funding concerns will also affect training, especially for people from underrepresented groups.